Home Publications Research Grants Inventions & Patents Awards Additional Research Activities Faculties & Institutions Research Areas

TCCIA: a comprehensive resource for exploring CircRNA in cancer immunotherapy

Wang S, Xiong Y, Zhang Y, Wang H, Chen M, Li J, Luo P, Luo YH, Hecht M, Frey B, Gaipl U, Li X, Zhao Q, Ma H, Zhou J (2024)

---

Publication Type: Journal article

Publication year: 2024

Journal

Book Volume: 12

Journal Issue: 1

DOI: 10.1136/jitc-2023-008040

Abstract

BACKGROUND: Immunotherapies targeting immune checkpoints have gained increasing attention in cancer treatment, emphasizing the need for predictive biomarkers. Circular RNAs (circRNAs) have emerged as critical regulators of tumor immunity, particularly in the PD-1/PD-L1 pathway, and have shown potential in predicting immunotherapy efficacy. Yet, the detailed roles of circRNAs in cancer immunotherapy are not fully understood. While existing databases focus on either circRNA profiles or immunotherapy cohorts, there is currently no platform that enables the exploration of the intricate interplay between circRNAs and anti-tumor immunotherapy. A comprehensive resource combining circRNA profiles, immunotherapy responses, and clinical outcomes is essential to advance our understanding of circRNA-mediated tumor-immune interactions and to develop effective biomarkers. METHODS: To address these gaps, we constructed The Cancer CircRNA Immunome Atlas (TCCIA), the first database that combines circRNA profiles, immunotherapy response data, and clinical outcomes across multicancer types. The construction of TCCIA involved applying standardized preprocessing to the raw sequencing FASTQ files, characterizing circRNA profiles using an ensemble approach based on four established circRNA detection tools, analyzing tumor immunophenotypes, and compiling immunotherapy response data from diverse cohorts treated with immune checkpoint blockades (ICBs). RESULTS: TCCIA encompasses over 4,000 clinical samples obtained from 25 cohorts treated with ICBs along with other treatment modalities. The database provides researchers and clinicians with a cloud-based platform that enables interactive exploration of circRNA data in the context of ICB. The platform offers a range of analytical tools, including browse of identified circRNAs, visualization of circRNA abundance and correlation, association analysis between circRNAs and clinical variables, assessment of the tumor immune microenvironment, exploration of tumor molecular signatures, evaluation of treatment response or prognosis, and identification of altered circRNAs in immunotherapy-sensitive and resistant tumors. To illustrate the utility of TCCIA, we showcase two examples, including circTMTC3 and circMGA, by employing analysis of large-scale melanoma and bladder cancer cohorts, which unveil distinct impacts and clinical implications of different circRNA expression in cancer immunotherapy. CONCLUSIONS: TCCIA represents a significant advancement over existing resources, providing a comprehensive platform to investigate the role of circRNAs in immuno-oncology.

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Wang, S., Xiong, Y., Zhang, Y., Wang, H., Chen, M., Li, J.,... Zhou, J. (2024). TCCIA: a comprehensive resource for exploring CircRNA in cancer immunotherapy. Journal for ImmunoTherapy of Cancer, 12(1). https://doi.org/10.1136/jitc-2023-008040

MLA:

Wang, Shixiang, et al. "TCCIA: a comprehensive resource for exploring CircRNA in cancer immunotherapy." Journal for ImmunoTherapy of Cancer 12.1 (2024).

BibTeX: Download